Impact of Cannabis Retail Environment on Treatment Outcomes for Cannabis Use Disorder
This study examines cannabis use disorder treatment outcomes in young adults and how they are influenced by environmental cannabis exposure. Digital cannabis treatment efficacy varies significantly with exposure to cannabis retailers. Understanding these…
What This Lancet Review Really Says About Cannabinoids in Psychiatry
A new Lancet Psychiatry review examined 54 randomized trials of cannabinoids for mental disorders and substance use disorders, and the evidence was thinner than many public claims suggest. A few outcomes showed signals, especially in cannabis use…
AEF0117 THC Interaction Trial Withdrawn: Implications for Selective CB1 Modulation
The withdrawal of the AEF0117 trial delays progress in selective CB1 receptor modulation for managing THC-related effects. This setback impacts potential pharmacological treatments for cannabis use disorder. Clinicians and patients face longer timelines…
Cannabis Use Disorder Clinical Trial Pipeline Gains Momentum
The cannabis use disorder treatment pipeline is gaining momentum with new clinical trials advancing targeted therapies. Research focuses on developing pharmacotherapies for cannabis addiction. This progress addresses the urgent need for evidence-based…